Post-Conference Perspectives: Updates on the Treatment of EGFR Mutant Early-Stage and Advanced NSCLC

Solange Peters, MD, PhD, and Tony SK Mok, MD, delve into the importance of molecular testing for EGFR mutant non-small cell lung cancer, including guidelines and commonly found barriers.

Drs Peters and Mok discuss adjuvant therapy for patients with early-stage EGFR mutant NSCLC and the impact of the ADAURA clinical trial on how we treat this disease.

Dr Mok finishes our discussion on the ADAURA trial, and Dr Peters delves into selecting the right adjuvant therapy for a patient with early-stage EGFR mutant NSCLC.

Tony SK Mok, MD, and Solange Peters, MD, PhD, relay the available treatment options for EGFR mutant NSCLC—both early and advanced stages.

Drs Mok and Peters explain the updates seen in the treatment landscape for EGFR mutant advanced-stage NSCLC.

Solange Peters, MD, PhD, and Tony SK Mok, MD, discuss what they’re looking forward to in the future for treating both stages of EGFR mutant NSCLC and give advice to colleagues treating this disease.